Hotchkis & Wiley Capital Management
SRPT icon

Hotchkis & Wiley Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Hotchkis & Wiley Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Buy
565,720
+5,570
+1% +$105K 0.03% 278
2026
Q1 		$12.2M Buy
+560,150
New +$10.8M 0.04% 182

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Hotchkis & Wiley Capital Management's SRPT Position: Q2 2026 in Review

Hotchkis & Wiley Capital Management increased its Sarepta Therapeutics (SRPT) stake by 0.99% in Q2 2026, buying an estimated $105K and bringing the position to 565,720 shares worth $10.2M. The position accounts for 0.03% of the portfolio, ranked #278.

Hotchkis & Wiley Capital Management first reported a position in SRPT in Q1 2026 and has held it in 2 quarters since. The position peaked at $12.2M in Q1 2026. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Hotchkis & Wiley Capital Management held 565,720 shares of Sarepta Therapeutics worth $10.2M as of Q2 2026.
  • Hotchkis & Wiley Capital Management bought 5,570 Sarepta Therapeutics shares in Q2 2026, an estimated $105K.
  • Sarepta Therapeutics made up 0.03% of Hotchkis & Wiley Capital Management's portfolio in Q2 2026, its #278 holding.
  • Hotchkis & Wiley Capital Management first reported a position in Sarepta Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Hotchkis & Wiley Capital Management's Sarepta Therapeutics position peaked at $12.2M in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Hotchkis & Wiley Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.